Initial screening of medications for efficacy in treating drug dependence may be accomplished more efficiently by using novel approaches that combine the practical advantages of within-subject laboratory studies with the clinical validity provided by clinical trials. A priori selection of functional gene variants associated with the pharmacokinetic or pharmacodynamic effects of a medication may aid this effort by controlling for individual variability as to clinical response or adverse effects; however, there are limitations to this approach, and these should be carefully considered.